Recovery of fat following a switch to nucleoside reverse transcriptase inhibitor-sparing therapy in patients with lipoatrophy: Results from the 96-week randomized ANRS 108 NoNuke Trial

HIV Medicine

Volumn 9, Issue 8, 2008, Pages 625-635

  Valantin, Marc Antoine ^a,b   Lanoy, E ^b,c   Bentata, M ^d   Kalmykova, O ^b,c   Boutekadjirt, A ^a,d   Allavena, C ^e,e   Rozenbaum, W ^f   Peytavin, G ^g   Amellal, B ^a   Calvez, V ^a,c   Costagliola, D ^b,c   Katlama, C ^a,b,c   Valantin, M A ^a   Dominguez, S ^a   Honore P ^d   Monssouri, R ^d   Rouges, F ^d   Raffi, F ^e   Billaud, E ^e   Bonnet, B ^e   Hue, H ^e   Reliquet, V ^e   Molina, J M ^f   Furco, A ^f   Ponscarme, D ^f   Yeni, P ^g   Matheron, S ^g   Gerbe, J ^g   Pahlavan, G ^g   Delfraissy, J F ^h   Poirier, S ^h   Quertainmont, Y ^h   Simon, A ^a   Bonmarchand, M ^a   Faller, J P ⁱ   Eglinger, P ⁱ   Perre P ^j   Remy, G ^k   Rouger, C ^k   Slama, L ^l   Chakvetadze, E ^l   Vittecoq, D ^m   Escaut, L ^m   Caulin, C ⁿ   Delcey, V ⁿ   Diemer, M ⁿ   Rami, A ⁿ   Hoen, B ^o   Estavoyer, J M ^o   Devidas, A ^p   Chevodon, P ^p   Kousignian, P ^p   Turpaulg, I ^p   Salmon Ceron D ^a   Benammar, N ^a   Bernasconi, C ^a   Grenier, P ^d   Dion, E ^d   Brauner, M ^e   Messiat, E ^e   Dupas, B ^e   Caillon, F ^f   De Kerviler, E ^g   Schauman Clayes, E ⁱ   Silbermann, O ⁱ   Chague D ^k   Marsault, B ^l   Lebreton, C ^l   Bellin Bertholier, M F ^m   Soyer, P ^o   Godin, S ^p   Amrar Vennier, F ^p   Drape J L ^e   more..

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b INSERM   (France)

^c SORBONNE UNIVERSITÉ   (France)

^d AVICENNE HOSPITAL   (France)

^e Department of Clinical Infectious and Tropical Diseases ^*

^f SAINT LOUIS HOSPITAL   (France)

^g BICHAT HOSPITAL   (France)

^h BICÊTRE HOSPITAL   (France)

ⁱ centre hospitalier Nord Franche Comté   (France)

^j CHD de la Roche sur Yon   (France)

^k HÔPITAL TENON   (France)

^l HÔPITAL PAUL BROUSSE   (France)

^m HÔPITAL LARIBOISIÈRE   (France)

ⁿ Hôpital de Besançon   (France)

^o CENTRE HOSPITALIER SUD FRANCILIEN   (France)

^p Hôpital La Roche sur Yon ^*  (France)

more..

Author keywords

HIV complications; Lipoatrophy; NRTI sparingregimen

Indexed keywords

AMPRENAVIR; ANTILIPEMIC AGENT; EFAVIRENZ; GLUCOSE; INDINAVIR; LOPINAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; ZIDOVUDINE;

ADULT; ARTERY DISEASE; ARTICLE; BODY FAT DISTRIBUTION; BODY MASS; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FLU LIKE SYNDROME; FOLLOW UP; HEART INFARCTION; HEPATITIS A; HEPATITIS C; HERPES SIMPLEX; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HYPERTRIGLYCERIDEMIA; INTRAABDOMINAL FAT; ISCHEMIC HEART DISEASE; JAW DISEASE; MAJOR CLINICAL STUDY; MALARIA; MALE; NEPHROLITHIASIS; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; OVARY CARCINOMA; PERICARDITIS; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; SIDE EFFECT; SKINFOLD THICKNESS; SUBCUTANEOUS FAT; TREATMENT DURATION; VIRUS LOAD; WAIST CIRCUMFERENCE; WAIST HIP RATIO;

EID: 52649108696     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2008.00606.x     Document Type: Article

References (32)

1. Carr A, Samaras K, Burton S et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998; 12: F51-F58.
2. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: A cohort study. Lancet 1999; 353: 2093-2099.
3. Rakotoambinina B, Medioni J, Rabian C, Jubault V, Jais JP, Viard JP. Lipodystrophic syndromes and hyperlipidemia in a cohort of HIV-1-infected patients receiving triple combination antiretroviral therapy with a protease inhibitor. J Acquir Immune Defic Syndr 2001; 27: 443-449.
4. Saves M, Raffi F, Capeau J et al. Factors related to lipodystrophy and metabolic alterations in patients with human immunodeficiency virus infection receiving highly active antiretroviral therapy. Clin Infect Dis 2002; 34: 1396-1405.
5. Duran S, Saves M, Spire B et al. Failure to maintain long-term adherence to highly active antiretroviral therapy: The role of lipodystrophy. AIDS 2001; 15: 2441-2444.
6. Chene G, Angelini E, Cotte L et al. Role of long-term nucleoside-analogue therapy in lipodystrophy and metabolic disorders in human immunodeficiency virus-infected patients. Clin Infect Dis 2002; 34: 649-657.
7. Mallal SA, John M, Moore CB, James IR, McKinnon EJ. Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection. AIDS 2000; 14: 1309-1316.
8. Saint-Marc T, Partisani M, Poizot-Martin I et al. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy. AIDS 1999; 13: 1659-1667.
9. Brinkman K, Smeitink JA, Romijn JA, Reiss P. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet 1999; 354: 1112-1115.
10. Martin JL, Brown CE, Matthews-Davis N, Reardon JE. Effects of antiviral nucleoside analogs on human DNA polymerases and mitochondrial DNA synthesis. Antimicrob Agents Chemother 1994; 38: 2743-2749.
11. Nolan D, Hammond E, Martin A et al. Mitochondrial DNA depletion and morphologic changes in adipocytes associated with nucleoside reverse transcriptase inhibitor therapy. AIDS 2003; 17: 1329-1338.
12. Pace CS, Martin AM, Hammond EL, Mamotte CD, Nolan DA, Mallal SA. Mitochondrial proliferation, DNA depletion and adipocyte differentiation in subcutaneous adipose tissue of HIV-positive HAART recipients. Antiviral Ther 2003; 8: 323-331.
13. Shikuma CM, Hu N, Milne C et al. Mitochondrial DNA decrease in subcutaneous adipose tissue of HIV-infected individuals with peripheral lipoatrophy. AIDS 2001; 15: 1801-1809.
14. Johnson AA, Ray AS, Hanes J et al. Toxicity of antiviral nucleoside analogs and the human mitochondrial DNA polymerase. J Biol Chem 2001; 276: 40847-40857.
15. Kakuda TN. Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity. Clin Ther 2000; 22: 685-708.
16. Dube MP, Parker RA, Tebas P et al. Glucose metabolism, lipid, and body fat changes in antiretroviral-naïve subjects randomized to nelfinavir or efavirenz plus dual nucleosides. AIDS 2005; 19: 1807-1818.
17. Joly V, Flandre P, Meiffredy V et al. Increased risk of lipoatrophy under stavudine in HIV-1-infected patients: Results of a substudy from a comparative trial. AIDS 2002; 16: 2447-2454.
18. Martin A, Smith DE, Carr A et al. Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: The MITOX Extension Study. AIDS 2004; 18: 1029-1036.
19. Carr A, Workman C, Smith DE et al. Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: A randomized trial. JAMA 2002; 288: 207-215.
20. McComsey GA, Ward DJ, Hessenthaler SM et al. Improvement in lipoatrophy associated with highly active antiretroviral therapy in human immunodeficiency virus-infected patients switched from stavudine to abacavir or zidovudine: The results of the TARHEEL study. Clin Infect Dis 2004; 38: 263-270.
21. Moyle GJ, Sabin CA, Cartledge J et al. A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy. AIDS 2006; 20: 2043-2050.
22. Murphy R, Zhang J, Hafner R et al. Peripheral and visceral fat changes following a treatment switch to a nonthymidine analogue or nucleoside-sparing regimen in patients with peripheral lipoatrophy: 48-week final results of ACTG A5110, a prospective, randomized multicenter clinical trial. 13th Conference on Retroviruses and Opportunistic Infections. Denver, CO, February 2006 [Abstract 755].
23. Wohl AR, Garland WH, Valencia R et al. A randomized trial of directly administered antiretroviral therapy and adherence case management intervention. Clin Infect Dis 2006; 42: 1619-1627.
24. Tebas P, Zhang J, Yarasheski K et al. Switching to a protease inhibitor-containing, nucleoside-sparing regimen (lopinavir/ritonavir plus efavirenz) increases limb fat but raises serum lipid levels: results of a prospective randomized trial (AIDS Clinical Trial Group 5125s). J Acquir Immune Defic Syndr 2007; 45: 193-200.
25. Casula M, Bosboom-Dobbelaer I, Smolders K et al. Infection with HIV-1 induces a decrease in mtDNA. J Infect Dis 2005; 191: 1468-1471.
26. McComsey GA, Paulsen DM, Lonergan JT et al. Improvements in lipoatrophy, mitochondrial DNA levels and fat apoptosis after replacing stavudine with abacavir or zidovudine. AIDS 2005; 19: 15-23.
27. Kim M, Leclercq P, Lanoy E et al. A 6-month interruption of antiretroviral therapy improves adipose tissue function in HIV-infected patients. ANRS EP29 Lipostop Study. Antiviral Ther 2007; 12: 1273-1283.
28. Fischl MA, Collier AC, Mukherjee AL et al. Randomized open-label trial of two simplified, class-sparing regimens following a first suppressive three or four-drug regimen. AIDS 2007; 21: 325-333.
29. Negredo E, Molto J, Burger D et al. Lopinavir/ritonavir plus nevirapine as a nucleoside-sparing approach in antiretroviral-experienced patients (NEKA Study). J Acquir Immune Defic Syndr 2005; 38: 47-52.
30. Allavena C, Ferre V, Brunet-Francois C et al. Efficacy and tolerability of a nucleoside reverse transcriptase inhibitor-sparing combination of lopinavir/ritonavir and efavirenz in HIV-1-infected patients. J Acquir Immune Defic Syndr 2005; 39: 300-306.
31. Riddler SA, Haubrich R, DiRienzo G et al. A prospective, randomized, phase III trial of NRTI-, PI-, and NNRTI-sparing regimens for initial treatment of HIV-1 infection-ACTG 5142. XVI International AIDS Conference. Toronto, August 2006 [Abstract THLB0204].
32. Duvivier C, Ghosn J, Assoumou L et al. Lower rate of virological suppression in naïve patients initiating HAART with NRTI-sparing regimen compared to standard NRTI-containing regimen: Results from Hippocampe-ANRS 121 Trial. 10th European AIDS Clinical Society Conference. Dublin, November 2005 [Abstract PS1/3].